{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:09:57Z","timestamp":1790662197621,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2011,4,8]],"date-time":"2011-04-08T00:00:00Z","timestamp":1302220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Symptomatic burden from constitutional symptoms, anemia, and splenomegaly\u2010related symptoms are common and morbidity inducing in patients with myelofibrosis (MF). The authors previously developed a MF\u2010specific instrument for capturing the burden of MF\u2010associated disease\u2010related symptoms, the Myelofibrosis Symptom Assessment Form.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The authors evaluated the usefulness of serial administration of the Myelofibrosis Symptom Assessment Form as an instrument for the assessment of symptomatic burden and improvement in conjunction with the therapeutic clinical trial of the open label phase 2 trial of the JAK1 and JAK2 inhibitor INCB018424 in patients with MF.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>The analysis cohort of 87 patients treated in this trial demonstrated that the instrument was comprehensive and sensitive to symptoms present at trial enrollment. In addition, baseline Myelofibrosis Symptom Assessment Form symptom scores correlated well with objective parameters such as splenomegaly and impaired performance status assessed by the 6\u2010minute walk test. Serial administration while on therapy with INCB018424 demonstrated the instrument to be sensitive to symptomatic change, and that improvements in symptoms correlated well with objective improvements in both weight loss and performance status (6\u2010minute walk test).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>The use of the Myelofibrosis Symptom Assessment Form in this phase 2 trial helped characterize the symptomatic improvements observed with use of INCB018424 in MF patients. In an era of many targeted therapies undergoing testing for MF with potential symptomatic benefit, the Myelofibrosis Symptom Assessment Form may provide a useful tool for objective symptomatic assessment and potentially allow some nonrandomized comparison between therapeutic agents. Cancer 2011;. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26129","type":"journal-article","created":{"date-parts":[[2011,4,8]],"date-time":"2011-04-08T13:04:46Z","timestamp":1302267886000},"page":"4869-4877","source":"Crossref","is-referenced-by-count":47,"title":["Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement"],"prefix":"10.1002","volume":"117","author":[{"given":"Ruben A.","family":"Mesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amylou","family":"Dueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Vaddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Erickson\u2010Viitanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh D.","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,4,8]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004273421706"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22365"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.01.035"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404948"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"a755","DOI":"10.1182\/blood.V114.22.755.755","article-title":"A phase I evaluation of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden","volume":"114","author":"Pardanani AD","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90182-1"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02918.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2928"},{"key":"e_1_2_6_19_2","first-page":"595","article-title":"Danazol treatment of idiopathic myelofibrosis with severe anemia","volume":"85","author":"Cervantes F","year":"2000","journal-title":"Haematologica."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-195974"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"a3905","DOI":"10.1182\/blood.V114.22.3905.3905","article-title":"Phase I dose\u2010escalation trial of SB1518, a novel JAK2\/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post\u2010essential thrombocythemia\/polycythemia vera myelofibrosis","volume":"114","author":"Verstovsek S","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"a308","DOI":"10.1182\/blood.V114.22.308.308","article-title":"A phase I study of LBH589, a novel histone deacetylase inhibitor in patients with primary myelofibrosis (PMF) and post\u2010polycythemia\/essential thrombocythemia myelofibrosis (post\u2010PV\/ET MF)","volume":"114","author":"Mascarenhas J","year":"2009","journal-title":"Blood"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"a307","DOI":"10.1182\/blood.V114.22.307.307","article-title":"RAD001, an inhibitor of mTOR, shows clinical activity in a phase I\/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera\/essential thrombocythemia myelofibrosis (PPV\/PET MF)","volume":"114","author":"Vannucchi AM","year":"2009","journal-title":"Blood."},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"a2911","DOI":"10.1182\/blood.V114.22.2911.2911","article-title":"Phase 1\/2 dose finding study of pomalidomide in myelofibrosis","volume":"114","author":"Mesa RA","year":"2009","journal-title":"Blood."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26129","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:06:11Z","timestamp":1760267171000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26129"}},"subtitle":["Performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial"],"short-title":[],"issued":{"date-parts":[[2011,4,8]]},"references-count":23,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1002\/cncr.26129"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26129","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,8]]}}}